Relationship between Development of Nephrotoxicity and Blood Concentration of Cyclosporine A in Bone-Marrow Transplanted Recipients Who Received the Continuous Intravenous Infusion

Access this Article

Author(s)

Abstract

This study was undertaken to investigate the relationship between blood concentration of cyclosporine A (CsA), administered intravenously by a 24-h continuous infusion, and drug-induced nephrotoxicity or hepatotoxicity. It was investigated retrospectively in 8 patients who had received an allogeneic bone marrow transplant (BMT). The correlation between daily doses and blood concentration of CsA was not significant. Then, the data of blood concentration of CsA and renal or liver function test result were divided into 5-d periods from the date of transplantation, and the mean value for each period was calculated. The maximum values of blood urea nitrogen (BUN) and serum creatinine (SCr) were consistently observed only after the period when the 5-d mean CsA concentration reached the peak level: the maximum BUN and SCr values were witnessed at Periods 2 to 10 and at Periods 1 to 9, respectively. On the other hand, no consistent correlation was found between the 5-d mean CsA concentrations and liver function test result. We also investigated the relationship between renal function and the cumulative dose or <i>AUC</i> of CsA. The parameters of renal function tests reached peak levels at the cumulative dose of 4000 to 10000 mg and at the cumulative <i>AUC</i> of 280000 to 660000 ng/ml·h. These results suggest that: 1) a deterioration of renal function occurs usually after the peak blood concentration of CsA is attained, and 2) the monitoring of the blood concentration of CsA is useful in predicting renal dysfunction in post-BMT patients.

Journal

  • Biological and Pharmaceutical Bulletin

    Biological and Pharmaceutical Bulletin 26(8), 1115-1119, 2003-08-01

    The Pharmaceutical Society of Japan

References:  12

  • <no title>

    FARH A.

    Clin. Pharmacokinet. 24, 472-495, 1993

    Cited by (1)

  • <no title>

    CAMPANA C.

    Clin. Pharmacokinet. 30, 141-179, 1996

    Cited by (2)

  • <no title>

    ENGLISH J.

    Transplantation 44, 135-141, 1987

    Cited by (1)

  • <no title>

    STEINER S.

    Biochem. Pharmacol. 51, 253-258, 1996

    Cited by (1)

  • <no title>

    TALLMAN M. S.

    Transplantation 45, 810-813, 1988

    Cited by (1)

  • <no title>

    MILLER K. B.

    Ann. Hematol. 68, 15-20, 1994

    Cited by (1)

  • <no title>

    TRULL A.

    Clin. Chem. 36, 1474-1478, 1990

    Cited by (1)

  • <no title>

    CHRISTIANS U.

    Eur. J. Pharmacol. 41, 291-296, 1991

    Cited by (1)

  • <no title>

    PULLA B.

    Renal Fail. 20, 421-435, 1998

    Cited by (1)

  • <no title>

    MIRALBELL R.

    J. Clin. Oncol. 14, 579-585, 1996

    Cited by (1)

  • <no title>

    PTACHININSKI R. J.

    Clin. Pharmacokin. 11, 107-132, 1986

    Cited by (1)

  • <no title>

    LIESVELD J

    Bone Marrow Transplant 24, 511-516, 1999

    DOI  Cited by (3)

Cited by:  4

Codes

  • NII Article ID (NAID)
    110003655061
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    09186158
  • NDL Article ID
    6620123
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-V41
  • Data Source
    CJP  CJPref  NDL  NII-ELS  J-STAGE 
Page Top